Clinical trial · Observational
Vascular Dysfunction and Antiangiogenic Therapy
Micro and Macro Vascular Dysfunction Induced by Antiangiogenic Therapy: Identification of New Vascular Biomarkers (DYVA-AAGG)
NCT02161978CI-TRIAL-00041476DYVA-AAGGcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
project is a pilot prospective, longitudinal, before-after, open label multicentric study.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| CML (Chronic Myelogenous Leukemia) | Chronic Myeloid Leukemia, BCR-ABL1 Positive | ALIAS | 0.90 |
| Endothelial Dysfunction | — | UNRESOLVED | — |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
| Tumor Angiogenesis | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Changes induced by antiangiogenic drugs and tyrosine kinase inhibitor in the vascular ultrasound variables
- timeFrame
- 24 months
- description
- arterial stiffness, diameter and resistance will be performed using echotracking technologies.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Men and women \> 18 years old treated for a solid tumor (kidney, pancreas, breast, lungs, skin) with line antiangiogneic therapy and hemopathy * Antiangiogneic therapy can be: bevacizumab, anti- (e.g. sunitinib, sorafenib), proteinate kinases inhibitor (e.g.temsirolimus ) or everolimus or any new allowed therapy with expected antiangiogenic properties and tyrosine kinase inhibitor. * Expected life span \> 6 months * Clinical state allowing investigations * A blood glucose and lipid tests within the last 3 months Exclusion Criteria: * Informed consent not obtained * Patients presenting a clinical state which does not allow for the performance of the vascular investigations (agitation, cutaneous wound, major asthenia, acute dyspnoea, cadiac arhythmia) * Pregnant women * Patients \> 18 yrs old protected by the french law * Patients without national health insurance * Patients included in another biomedical study (this criteria is relative to the other studies)
References
Publications (0)
Data not yet available
No reference posted for this study.